Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

Hovione DMFs at FDA

List of DMFs

Page
Read more

Large Dose DPI

Disposable DPI for high dose drug delivery.

Page
Read more

Spray congealing

Spray congealing, also known as spray cooling, is a solvent free process that transforms a melt into well defined spherical particles.

Page
Read more